Media release
From: Springer NatureVirology: Coronavirus structures provide clues to SARS-CoV-2 evolution
The structures of the spike glycoproteins, which enable a virus to bind to and enter cells, for SARS-CoV-2 and the closely related bat virus RaTG13 are characterized in a paper in Nature Structural & Molecular Biology. The structures provide further information about how the SARS-CoV-2 spike evolved and may provide insights for vaccine design.
Bat coronaviruses have been identified as the likely evolutionary precursor to SARS-CoV-2, and previous studies have identified the bat virus RaTG13 as the closest known relative of SARS-CoV-2. However, it is not known how the virus evolved to infect humans nor whether this happened via an intermediary host or through direct transmission.
Antoni Wrobel, Donald Benton and colleagues compared the spike glycoproteins from SARS-CoV-2 and RaTG13. They found that, although the structures were similar, SARS-CoV-2 has a more stable form of the spike glycoprotein and is able to bind approximately 1,000 times more tightly to the human receptor protein ACE2. The authors also found that the presence of a furin cleavage site in the SARS-CoV-2 spike could be advantageous for the virus, as it may facilitate the virus binding to the receptor on cells. On the basis of their observations, the authors suggest that a bat virus similar to RaTG13 would be unlikely to infect human cells, which supports the theory that SARS-CoV-2 evolved from a recombination of distinct coronavirus genomes.
The authors note that their structure of the SARS-CoV-2 spike glycoprotein is presented in high resolution and is nearly complete, with more external loops than previously reported structures, which may provide important insights for vaccine design.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.
Dr Francesca Di Giallonardo is a Postdoctoral Fellow in the Immunovirology and Pathogenesis Program at the Kirby Institute, UNSW Sydney